Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations

RAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer (CRC) but RAF inhibitor combinations have demonstrated improved efficacy, likely through superior suppression of MAPK signaling. The first identified mechanisms of acquired resistance to these combinations all promote MAPK rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahronian, Leanne G., Corcoran, Ryan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845183/
https://www.ncbi.nlm.nih.gov/pubmed/27308562
http://dx.doi.org/10.1080/23723556.2015.1048405
_version_ 1782428894139252736
author Ahronian, Leanne G.
Corcoran, Ryan B.
author_facet Ahronian, Leanne G.
Corcoran, Ryan B.
author_sort Ahronian, Leanne G.
collection PubMed
description RAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer (CRC) but RAF inhibitor combinations have demonstrated improved efficacy, likely through superior suppression of MAPK signaling. The first identified mechanisms of acquired resistance to these combinations all promote MAPK reactivation, underscoring the MAPK pathway as a critical target in BRAF-mutant CRC.
format Online
Article
Text
id pubmed-4845183
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-48451832016-06-15 Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations Ahronian, Leanne G. Corcoran, Ryan B. Mol Cell Oncol Commentary RAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer (CRC) but RAF inhibitor combinations have demonstrated improved efficacy, likely through superior suppression of MAPK signaling. The first identified mechanisms of acquired resistance to these combinations all promote MAPK reactivation, underscoring the MAPK pathway as a critical target in BRAF-mutant CRC. Taylor & Francis 2015-05-21 /pmc/articles/PMC4845183/ /pubmed/27308562 http://dx.doi.org/10.1080/23723556.2015.1048405 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Commentary
Ahronian, Leanne G.
Corcoran, Ryan B.
Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
title Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
title_full Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
title_fullStr Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
title_full_unstemmed Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
title_short Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
title_sort effective mapk inhibition is critical for therapeutic responses in colorectal cancer with braf mutations
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845183/
https://www.ncbi.nlm.nih.gov/pubmed/27308562
http://dx.doi.org/10.1080/23723556.2015.1048405
work_keys_str_mv AT ahronianleanneg effectivemapkinhibitioniscriticalfortherapeuticresponsesincolorectalcancerwithbrafmutations
AT corcoranryanb effectivemapkinhibitioniscriticalfortherapeuticresponsesincolorectalcancerwithbrafmutations

Ejemplares similares